What science can do
A global science-led business delivering medicines to patients through innovative science and excellence in development and commercialisation.

Our Purpose is to push the boundaries of science to deliver life-changing medicines. We want to be valued and trusted by our stakeholders as a source of great medicines over the long term.

Our strategic priorities
Reflect how we are working to achieve our Purpose
1. Achieve Scientific Leadership
2. Return to Growth
3. Be a Great Place to Work

A science-led innovation strategy
Strategy from page 18 and Key Performance Indicators from page 20.

Distinctive R&D capabilities:
Small molecules, oligonucleotides and other emerging drug platforms, as well as biologic medicines, including immunotherapies, and innovative delivery devices

Broad R&D platform in three main areas
Achieve Scientific Leadership from page 25 and Therapy Area Review from page 50.

Oncology
Our ambition is to push the boundaries of science to change the practice of medicine, transform the lives of patients living with cancer, and ultimately eliminate cancer as a cause of death

Cardiovascular, Renal and Metabolism
As science uncovers commonalities between cardiovascular, renal and metabolic diseases and their associated complications, we aim to transform how they are understood and treated

Respiratory
Our research focuses on the underlying causes of respiratory diseases, using new modalities to pursue previously hard-to-reach targets, with the ambition of achieving remission or even cures for patients

Other Disease Areas
We are also selectively active in the areas of autoimmunity, neuroscience and infection

Portfolio of specialty and primary care products (Product Sales)

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>$6,028m</td>
<td>$6,710m</td>
<td>$4,911m</td>
</tr>
<tr>
<td>(Product Sales)</td>
<td>29% of total</td>
<td>32% of total</td>
<td>23% of total</td>
</tr>
<tr>
<td>2017: $4,024m</td>
<td>2016: $3,383m</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Sales growth of 50% (40% at CER), including:
  Imfinzi sales of $633 million, reflecting ongoing launches
  Lynparza sales of $647 million, representing growth of 118% (116% at CER), driven by expanded use in the treatment of ovarian cancer and first approvals for breast cancer
  Tagrisso sales of $1,860 million, representing growth of 95% (93% at CER) |

<table>
<thead>
<tr>
<th><strong>Cardiovascular, Renal and Metabolism</strong></th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Respiratory</strong></td>
<td>$6,710m</td>
<td>$4,911m</td>
<td>$3,400m</td>
</tr>
<tr>
<td>(Product Sales)</td>
<td>32% of total</td>
<td>23% of total</td>
<td>16% of total</td>
</tr>
<tr>
<td>2017: $4,726m</td>
<td>2016: $8,116m</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Sales growth of 4% in the year (3% at CER), including:
  Fasenra sales of $297 million, performing exceptionally well in the countries where it was launched
  Pulmicort sales growth of 9% (8% at CER) to $1,286 million
  Symbicort sales decline of 9% (10% at CER) to $2,561 million, as competitive price pressures in the US continued |

<table>
<thead>
<tr>
<th><strong>Other Disease Areas</strong></th>
<th>2018</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Other Disease Areas</strong></td>
<td>$3,400m</td>
<td>$4,156m</td>
<td>$5,067m</td>
</tr>
<tr>
<td>(Product Sales)</td>
<td>16% of total</td>
<td>21% of total</td>
<td>31% of total</td>
</tr>
<tr>
<td>2017: $4,156m</td>
<td>2016: $5,067m</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Sales declined by 18% (19% at CER) and represented 16% of total Product Sales, down from 31% in 2017</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sales growth of 50% (40% at CER), including:
  Imfinzi sales of $633 million, reflecting ongoing launches
  Lynparza sales of $647 million, representing growth of 118% (116% at CER), driven by expanded use in the treatment of ovarian cancer and first approvals for breast cancer
  Tagrisso sales of $1,860 million, representing growth of 95% (93% at CER)
Global commercial presence, with strength in Emerging Markets (Product Sales)

<table>
<thead>
<tr>
<th>Region</th>
<th>2017 Sales (m)</th>
<th>2016 Sales (m)</th>
<th>2015 Sales (m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emerging Markets</td>
<td>$6,891m</td>
<td>$6,149m</td>
<td>$5,794m</td>
</tr>
<tr>
<td>US</td>
<td>$6,876m</td>
<td>$7,169m</td>
<td>$7,365m</td>
</tr>
<tr>
<td>Europe</td>
<td>$4,459m</td>
<td>$4,753m</td>
<td>$5,064m</td>
</tr>
<tr>
<td>Established Rest of World</td>
<td>$2,823m</td>
<td>$3,081m</td>
<td>$3,096m</td>
</tr>
</tbody>
</table>

Product Sales increased by 12% (13% at CER). New Medicines represented 15% of Emerging Market sales in the year, up from 10% in 2017.

Product Sales declined by 11% (1% at CER). New Medicines represented 48% of Product Sales, up from 26% in 2017.

Product Sales declined by 6% (10% at CER), reflecting the entry of generic Crestor medicines in various markets in 2017 and continued competitive and price pressures.

Product Sales declined by 8% (9% at CER). New Medicines represented 24% of sales in the year, up from 13% in 2017. Performance reflected, in particular, the success of Tagrisso and Forxiga.

Our talented employees

Committed to attracting, retaining and developing a talented and diverse workforce united in the pursuit of our Purpose and living our Values

64,600 employees
2017: 61,100
2016: 59,700

44.6% of our senior roles are filled by women

102 manuscripts published by our scientists in high-impact peer-reviewed journals

Strategic R&D centres
1. Cambridge, UK (HQ)
2. Gaithersburg, MD, US
3. Gothenburg, Sweden
4. California, US
5. Boston, MA, US
6. Alderley Park and Macclesfield, UK
7. Shanghai, China
8. Osaka, Japan

A sustainable business

Committed to operating in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet

100% of employees trained in Code of Ethics

Our capital allocation priorities

Striking a balance between the interests of the business, our financial creditors and shareholders, and supporting our progressive dividend policy

Dividend per Ordinary Share for 2018

1st interim dividend: $0.90
Pence: 68.4
SEK: 7.92
Payment date: 10 September 2018

2nd interim dividend: $1.90
Pence: 146.8
SEK: 17.46
Payment date: 27 March 2019

Total dividend: $2.80
Pence: 215.2
SEK: 25.38
2017: $2.80
2016: $2.80